The purpose of this study is to assess efficacy of prolonged Full Disclosure ECG monitoring and signal analysis using advanced GSM telemetric technology to prescribe the most appropriate treatment of arrhythmia.
Non-invasive methods enabling long-term ECG monitoring in patients with paroxysmal symptoms, such as tachycardia or palpitations increase the probability of detecting infrequent but dangerous events with profound clinical significance. Patients with recommendation for the first catheter ablation of Paroxysmal Atrial Fibrillation in the reference center will be included in the study. Eligible patients will have 14-day telemetric ECG monitoring. Based on detected arrhythmia events, patient's medical history and available documentation the most appropriate treatment will be recommended. Patients will undergo invasive procedures of ablation or pacemaker implantation or can be treated pharmacologically. After the invasive treatment or initiation of pharmacotherapy the 14-day telemetric ECG monitoring will be repeated to assess efficacy of the treatment. Patients with no record of arrhythmia requiring treatment during the first 14 days ECG monitoring will terminate participation in the study. The referring physician will be informed. Further diagnosis or treatment should be performed at the referring physician's center according to the best clinical practice.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
360
Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
Universitair Ziekenhuis Brussel Centre for Heart- and Vascular diseases
Brussels, Belgium
RECRUITINGKlinika Kardiologii CMKP
Warsaw, Poland
RECRUITINGInstitute of Cardiology
Warsaw, Poland
RECRUITINGOccurence of atrial fibrillation
Confirmation of indication for catheter ablation of atrial fibrillation by detection of incidence of AF event during 14 days ECG monitoring
Time frame: 14 days since the start of monitoring
Therapy efficacy analysis
The mean atrial fibrillation burden reduction
Time frame: 14 days
Indication for treatment other than catheter ablation
Confirmation of indication for treatment other than catheter ablation such as: pacemaker or pharmacotherapy by detetion of: 1. arrhythmia other than AF qualifying for treatment 2. Bradycardia \< 40 BPM 3. Pauses \> 2,5 s on sinus rhythm or \> 3,5 on AF
Time frame: 14 days
Correlation of patient self assessment based on the Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale with cardiac arrhythmia occurrence.
Time frame: 14 days
Evaluation of stroke and bleeding risk factors incidence based on scores proposed in the European Society of Cardiology (ESC) guidelines: CHADS2VASC2 and HAS-BLED
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.